covariate | P-value | Risk ratio | 95 % CI |
---|---|---|---|
Sex (male, female) | 0.4 | 1.35 | (0.655, 2.043) |
Age (≤50 or younger,>50) | 0.13 | 2.49 | (1.300, 3.680) |
Tumor location Post1 | 0.75 | 1.16 | (0.244, 2.082) |
Tumor location Post2 | 0. 448 | 1.38 | (0.551, 2.201) |
Tumor location Post3 | 0.98 | 0 | (−1242.048, 1242.048) |
Tumor location Post4 | 0.99 | 0 | (−1596.148, 1596.148) |
Tumor location Post5 | 0.77 | 0.8 | (−0.692, 2.288) |
Tumor size (T1-T4) | 0.45 | 1.18 | (0.757, 1.595) |
Nodal metastasis (N0, N(+)) | 0.44 | 1.31 | (0.618, 2.006) |
Metastasis (M0, M(+)) | 0.69 | 0.05 | (0.760, 1.470) |
Clinical stage (I, II, III, IV) | 0.55 | 1.12 | (1.146, 2.200) |
Pathological grade | 0.06 | 1.67 | (0.244, 2.082) |
CD68+ macrophages counts in tumor nest (Low, High) | 0.01 | 3.08 | (2.236, 3.914) |
CD68+ macrophages counts in tumor stroma (Low, High) | 0.3 | 0.69 | (−0.010, 1.390) |
CD163+ macrophages counts in tumor nest (Low, High) | 0.02 | 2.83 | (1.991, 3.669) |
CD163+ macrophages counts in tumor stroma (Low, High) | 0.48 | 0.78 | (0.085, 1.473) |
CD68 expression in tumor (Negative, Low, High) | 0.97 | 1.01 | (0.555, 1.465) |
CD163 expression in tumor (Negative, Low, High) | 0 | 2.2 | (1.735, 2.667) |
E-cadherin expression in tumor (Negative, Low, High) | 0.61 | 0.89 | (0.465, 1.323) |
E-cadherin expression at the invasive front of tumor (Negative, Low, High) | 0.19 | 0.74 | (0.280, 1.1937) |
Vimentin expression in tumor (Negative, Low, High) | 0.01 | 1.79 | (1.373, 2.207) |
Vimentin expression at the invasive front of tumor (Negative, Low, High) | 0 | 1.88 | (1.474, 2.295) |